JBI-295

JBI-295 is a novel, orally bioavailable dual inhibitor targeting Lysine Specific Demethylase 1 (LSD1) and Histone Deacetylase isoforms 6 and 8 (HDAC6/8). Developed by Jubilant Biosys, the compound is designed to leverage the synergistic effects of epigenetic modulation in treating various malignancies. LSD1 is often overexpressed in tumors and inhibits differentiation, particularly in acute myeloid leukemia (AML), while HDAC6 and HDAC8 are involved in protein stability and gene expression. JBI-295 has demonstrated potent anti-proliferative activity in AML, multiple myeloma, and melanoma models, showing superior efficacy compared to selective HDAC6 inhibitors in vivo. It also exhibits potential in combination with immune checkpoint inhibitors like anti-PD-L1 antibodies.